Botox maker sees another jackpot in Latisse, due this month
(Newser) -
The company behind Botox sees another hit with the first federally approved drug for growing longer, fuller eyelashes, the
New York Times reports. The $120 monthly price tag for Latisse, based on a glaucoma drug, makes some analysts blink, particularly during recession. “If you think about it in terms...
More »
